Trial Profile
Interferon-alpha plus sorafenib versus sorafenib monotherapy as first-line treatment for metastatic clear cell renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Aug 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary) ; Interferon alpha
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 17 Aug 2015 New trial record